What is the Future of Alectinib in Cancer Treatment?
Ongoing research aims to further understand the mechanisms of resistance to ALK inhibitors and to develop next-generation inhibitors that can overcome these challenges. The continued development of combination therapies involving alectinib and other targeted agents or immunotherapies holds promise for improving outcomes for patients with ALK-positive NSCLC.
